Please use this identifier to cite or link to this item:
Title: Mefloquine prophylaxis prevents malaria during pregnancy: A double-blind, placebo-controlled study
Authors: F. Nosten
F. Ter Kuile
L. Maelankiri
T. Chongsuphajaisiddhi
L. Nopdonrattakoon
S. Tangkitchot
E. Boudreau
D. Bunnag
N. J. White
Shoklo Malaria Research Unit
Mahidol University
Academic Medical Centre, University of Amsterdam
Pharmaceutical Systems Inc.
John Radcliffe Hospital
Keywords: Medicine
Issue Date: 1-Jan-1994
Citation: Journal of Infectious Diseases. Vol.169, No.3 (1994), 595-603
Abstract: A double-blind, placebo-controlled study of mefloquine antimalarial prophylaxis in pregnancy ( > 20 weeks of gestation) was conducted in 339 Karen women living in an area of multidrug-resistant malaria transmission on the Thai-Burmese border. Mefloquine gave ≥86% (95% confidence interval [CI], 59%-94%) protection against Plasmodium falciparum and complete protection against Plasmodium vivax infections. Mefloquine prophylaxis was welltolerated; use of an initial loading dose (10 mg/kg) was associated with transient dizziness, but there were no other significant adverse effectson the mother, the pregnancy, or infant survivalor development(followed for 2 years). Falciparum malaria was associated with maternal anemia and a mean reduction in birth weight in gravidae I, II, and III of225 g (95%CI, 26-423). Maternal anemia at delivery(hematocrit < 30%) was associated with increased infant mortality: 26% versus 15% (relative risk, 1.9; 95% CI, 1.1-3.2). Mefloquine is safe and effective for antimalarial prophylaxis in the second half of pregnancy. © 1994 by The University of Chicago.
ISSN: 15376613
Appears in Collections:Scopus 1991-2000

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.